Reaction

Norovirus Infection reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,375 reports · 53 co-occurring drugs

As of the last recalculation, Norovirus Infection appears in 1,375 FAERS reports alongside 53 co-occurring drug terms. The strongest observed disproportionality signal is HUMAN IMMUNOGLOBULIN G (PRR 42.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Human Immunoglobulin G	55	42.0	42.1
Diphenhydramine Hydrochloride Capsule, Liquid Filled	37	26.9	27.0
Tacrolimus Ointment 0.1%	186	26.0	26.0
Tacrolimus Extended-Release Capsules	186	25.9	26.0
Teduglutide	20	22.8	22.8
Anti-Thymocyte Globulin (Rabbit)	12	22.7	22.7
Fludarabine Phosphate	56	22.4	22.5
Tacrolimus	194	21.7	21.7
Mycophenilic Acid	29	21.6	21.6
Everolimus Tablets	22	20.2	20.2
Mycophenolic Acid	38	18.5	18.5
Adrenalinum	48	18.1	18.1
Mycophenolate Mofetil	143	17.7	17.7
Mycophenolate Mofetil Hydrochloride	143	17.6	17.7
Sirolimus	14	15.9	15.9
Risankizumab-Rzaa	69	13.4	13.4
Ganciclovir	9	13.4	13.4
Ganciclovir Sodium	9	13.0	13.0
Cladribine	8	12.7	12.7
Busulfan	13	12.6	12.6
Valganciclovir Hydrochloride Powder,	10	12.5	12.5
Valganciclovir	15	12.2	12.2
Valganciclovir Hydrochloride	15	12.2	12.2
Epinephrine	50	12.0	12.0
Cyclobenzaprine Hydrochloride	7	11.8	11.9
Cetirizine Hcl	7	11.6	11.6
Thiotepa	7	11.1	11.2
Daspone	7	10.9	10.9
Dapsone Gel, 5%	7	10.9	10.9
Upadacitinib	52	10.0	10.0
Ifosfamide	14	10.0	10.0
Agalsidase Beta	5	8.2	8.2
Levocetirizine Dihydrochloride	12	7.6	7.6
Botulinum Toxin Type A	6	7.3	7.3
Ozanimod Hydrochloride	4	7.3	7.3
Irinotecan Hydrochloride	6	7.1	7.1
Mometasone Furoate And Formoterol Fumarate Dihydrate	7	6.8	6.8
Abiraterone	6	6.7	6.7
Ocrelizumab	26	6.4	6.5
Fexofenadine Hydrochloride	9	6.3	6.3
Acalabrutinib	5	6.3	6.3
Rimegepant Sulfate	5	6.0	6.0
Ofatumumab	12	5.5	5.5
Voclosporin	3	5.2	5.2
Siponimod	3	5.1	5.1
Avapritinib	4	5.0	5.0
Vigabatrin	4	4.2	4.2
Sarilumab	6	3.4	3.4
Relugolix	5	3.2	3.2
Tirzepatide	33	3.1	3.1
Guselkumab	6	2.5	2.5
Dupilumab	75	2.4	2.4
Pimavanserin Tartrate	6	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.